Overview
- Editors:
-
-
Michael F. Powell
-
Genentech, Inc., South San Francisco, USA
-
Mark J. Newman
-
Vaxcel, Inc., Norcross, USA
Access this book
Other ways to access
Table of contents (41 chapters)
-
-
- Mark J. Newman, Michael F. Powell
Pages 1-42
-
- Dale N. Lawrence, Karen L. Goldenthal, John W. Boslego, Donna K. F. Chandler, John R. La Montagne
Pages 43-60
-
- Jeanine L. Bussiere, George C. McCormick, James D. Green
Pages 61-79
-
-
- Patricia E. Fast, Leigh A. Sawyer, Susan L. Wescott
Pages 97-134
-
-
- Frederick R. Vogel, Michael F. Powell
Pages 141-228
-
- Rajesh K. Gupta, Bradford E. Rost, Edgar Relyveld, George R. Siber
Pages 229-248
-
- Stanley L. Hem, Joe L. White
Pages 249-276
-
- Gary Ott, Gail L. Barchfeld, David Chernoff, Ramachandran Radhakrishnan, Peter van Hoogevest, Gary Van Nest
Pages 277-296
-
-
- Deborah M. Lidgate, Noelene E. Byars
Pages 313-324
-
-
- Patricia J. Freda Pietrobon
Pages 347-361
-
- Raphael J. Mannino, Susan Gould-Fogerite
Pages 363-387
-
- Justin Hanes, Masatoshi Chiba, Robert Langer
Pages 389-412
-
- Noemi Santiago, Susan Haas, Robert A. Baughman
Pages 413-438
-
-
About this book
When my interest was first drawn to the phenomenon of vaccination for virus diseases in the late 1930s, the state of the art and the science of vaccine design was not far advanced beyond the time of Jenner at the end of the 18th century and of Pasteur a century later. In the 1930s it was still believed that for the induction of immunity to a virus-caused disease the experience of infection was required, but not for a toxin-caused disease such as diphtheria or tetanus, for which a chemically detoxified antigen was effective for immu nization. This prompted the question as to whether it might be possible to produce a similar effect for virus diseases using nonreplicating antigens. When in the 1930s and 1940s it was found possible to propagate influenza viruses in the chick embryo, protective effects could be induced without the need to experience infection by the use of a sufficient dose of a noninfectious influenza virus preparation. Later in the 1940s, it became possible to propagate polio and other viruses in cultures of human and monkey tissue and to immunize against other virus diseases in the same way. Later, with the advent of the era of molecular biology and genetic engineering, antigens and vaccines could be produced in new and creative ways, using either replicating or nonreplicating forms of the appropriate antigens for inducing a dose-related protective state.
Reviews
`This book should be very valuable to anyone interested in the basic design of vaccine strategies or the preclinical evaluation of novel vaccines and adjuvants.'
Doody's Journal
`I have little doubt that this book will become a standard reference for future development of vaccine formulations.'
European Journal of Pharmaceutics and Biopharmaceutics
Editors and Affiliations
-
Genentech, Inc., South San Francisco, USA
Michael F. Powell
-
Vaxcel, Inc., Norcross, USA
Mark J. Newman
